Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.